

## NOC2L RABBIT PAB

**Cat.#:** S217653

**Product Name:** Anti-NOC2L Rabbit Polyclonal Antibody

**Synonyms:** NIR; NET7; NET15

**UNIPROT ID:** Q9Y3T9 (Gene Accession - BC003555 )

**Background:** Histone modification by histone acetyltransferases (HAT) and histone deacetylases (HDAC) can control major aspects of transcriptional regulation. NOC2L represents a novel HDAC-independent inhibitor of histone acetyltransferase (INHAT)

**Immunogen:** Fusion protein of human NOC2L

**Applications:** ELISA, WB, IHC

**Recommended Dilutions:** IHC: 25-100;WB: 200-1000;ELISA: 1000-2000

**Host Species:** Rabbit

**Clonality:** Rabbit Polyclonal

**Isotype:** Immunogen-specific rabbit IgG


**Purification:** Antigen affinity purification

**Species Reactivity:** Human, Mouse


**Constituents:** PBS (without Mg<sup>2+</sup> and Ca<sup>2+</sup>), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

**Research Areas:** Epigenetics and Nuclear Signaling, Cancer


**Storage & Shipping:** Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human prostate cancer tissue using 217653(NOC2L Antibody) at a dilution of 1/20(Cytoplasm or Nucleus).




In comparison with the IHC on the left, the same paraffin-embedded Human prostate cancer tissue is first treated with the fusion protein and then with 217653(Anti-NOC2L Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffin-embedded Human breast cancer tissue using 217653(Anti-NOC2L Antibody) at a dilution of 1/20.



In comparison with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with fusion protein and then with D222774(Anti-NOC2L Antibody) at dilution 1/20.



Gel: 6%SDS-PAGE, Lysate: 40 µg;  
Lane: Hela cells;  
Primary antibody: 217653(NOC2L Antibody) at dilution 1/200;  
Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution;  
Exposure time: 5 seconds



# Product Description

Pioneering GTPase and Oncogene Product Development since 2010

---